GSK announced on Friday that its monoclonal antibody ‘Nucala’, or mepolizumab, has received approval from China's National ...

Mayo Clinic researchers have identified interleukin-23 receptor (IL-23R) as a significant biomarker of cellular senescence ...

The use of risankizumab after poor response to 2 interleukin-17 inhibitors, secukinumab, and ixekizumab, was safe and effective in plaque psoriasis.

Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of ...

General Surgery Department, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China Institute of Analytical Chemistry, ...

Hosts Slovakia meet Spain, Italy and Romania while holders England have Germany among their opponents after the draw was made at the Slovak Philharmonic Reduta Building in Bratislava. The draw ...

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology conditions, including psoriatic arthritis and inflammatory bowel disease.